BGPT: Paper Review: Tumor-associated macrophages in cancer: from mechanisms to application

Explore by Goal

Quick Explanation Copied

Skeptical, evidence-weighted review

This narrative review argues that TAMs are highly heterogeneous, plastic, and spatially organized regulators of tumor progression (growth, invasion, immune evasion, and therapy resistance), and it maps multiple TAM-targeting approaches (recruitment blockade, depletion, reprogramming, CAR-macrophages, metabolism and phagocytosis checkpoint modulation) to combination strategies with immunotherapy. Key strengths are mechanistic breadth and inclusion of single-cell/spatial biomarker concepts; key blind spots are the inherent limits of narrative synthesis, marker/annotation heterogeneity across studies, and the translational uncertainty of oversimplified “M1/M2” framing.

Primary paper: 10.1186/s43556-025-00396-y

Key background/corroboration anchors: macrophage ecology at the tumor interface

Long Explanation

Paper: “Tumor-associated macrophages in cancer: from mechanisms to application”

Metadata

DOI: 10.1186/s43556-025-00396-y

Received/Revised/Accepted: 5 Jul 2025 / 11 Dec 2025 / 12 Dec 2025 (from provided text)

Type: narrative review (no new primary data; “Not applicable” data availability in provided text)

Visual map: TAM roles ↔ mechanisms ↔ therapeutic levers

The review’s core structure can be expressed as a directed “cause → phenotype → outcome → target” graph, reflecting (i) TAM recruitment and differentiation, (ii) spatially structured functional programs, and (iii) intervention points spanning recruitment, depletion, reprogramming, phagocytosis checkpoints, and metabolism.

Citation anchors for the map’s logic

TAMs are described as the most prevalent innate immune population in tumors and centrally involved in progression/immune evasion; they originate from circulating monocytes and exhibit context-dependent functional duality
The review’s emphasis on abandoning strict binary polarization aligns with broader macrophage activation/polarization guidance
Spatial/SC integration is supported by pan-cancer atlas work showing TAM programs vary and relate to immunotherapy response

1) What the review claims (and where the confidence is highest)

1.1 Recruitment and “education” into tumor-relevant states

The review describes TAM influx being driven by chemokine/cytokine networks (e.g., CCL2/CCR2) and highlights self-reinforcing recruitment loops and crosstalk (tumor cells ↔ TAMs; TAMs ↔ TANs; CAFs ↔ TAMs) as a common mechanistic theme.

Example anchor: CCL2/CCR2 is presented as a recruitment axis in esophageal carcinogenesis with downstream immune-evasion implications .

1.2 Heterogeneity: beyond simplistic M1/M2 binaries

The review explicitly argues that anti- vs pro-tumor labeling is an oversimplification and that scRNA-seq can resolve functionally distinct TAM subsets. This is consistent with formal guidance that macrophage activation/polarization is better viewed as a spectrum with experimental constraints and nomenclature caveats .

Example anchor: defining FN1+ TAMs as a glioma-recurrence-associated subtype .

1.3 Mechanistic outputs: growth, invasion/metastasis, immune suppression, resistance

The review organizes mechanistic outputs into four core functional consequences. Strongest confidence tends to attach to mechanisms that are repeatedly observed across systems (cytokine/chemokine-driven immune modulation, checkpoint expression such as PD-L1, and feedback loops), rather than to any single biomarker.

Example anchor: PD-1 expressed by tumor-associated macrophages can inhibit phagocytosis and tumor immunity .

1.4 Application: TAM-targeting as part of combination strategies

The review claims that combination approaches (e.g., TAM recruitment/depletion/reprogramming with ICIs) can help overcome therapy resistance. It also emphasizes that clinical outcomes depend on selecting the relevant TAM subset(s) and managing systemic effects.

Example anchors (clinical translation constraints and mechanistic interference): pexidartinib combined with durvalumab may have limited effect partly due to FLT3-dependent DC differentiation impairment .

2) Critical appraisal (skeptical, evidence-based)

2.1 Narrative review epistemics

Because the paper is a narrative review with no new primary datasets (explicitly “Not applicable” data availability in provided text), the main risk is uneven coverage and citation bias. Mechanistically, the review’s breadth is helpful, but it makes it difficult to weight evidence formally across cancers, model systems, and TAM subset definitions.

2.2 Marker heterogeneity and annotation drift

The review highlights multiple biomarkers (e.g., TREM2, SPP1, CD163/CD206, MARCO), but in practice biomarker meaning can shift across platforms (IHC panels, scRNA-seq reference mapping, spatial algorithms) and across tumor types. This increases the chance of “category leakage,” where two studies calling the same marker-defined TAM subset may not represent identical functional states.

The review’s own stated move toward scRNA-seq/spatial specificity is an appropriate mitigation, but it doesn’t fully remove cross-study measurement mismatch (especially when “M2-like” or “anti-/pro-tumoral” labels persist).

The broader literature supports viewing polarization nomenclature as experimentally constrained rather than fixed .

2.3 Correlation vs causation in prognostic biomarker claims

The review discusses the prognostic value of TAM density/subsets and notes inconsistencies (notably across colorectal cancer). This is appropriate; however, narrative synthesis still risks over-weighting consistent-looking correlational patterns and under-weighting null/negative studies.

The presence of contradictory prognosis associations across cancers is consistent with TAM heterogeneity and spatial localization effects .

2.4 Translational pitfalls: depletion/reprogramming can alter “useful” immunity

A key translational blind spot is that macrophage targeting may unintentionally reduce beneficial antigen presentation or affect dendritic cell differentiation. The review mentions such constraints in the context of combination trials and limited clinical benefit for some TAM-pathway inhibitors; this aligns with mechanistic evidence that CSF-1R inhibition can impact DC differentiation .

2.5 “Application” scope: from benchmarks to actionable research design

The review’s practical value is strongest for structuring hypotheses and selecting candidate TAM intervention points (recruitment axes, checkpoint expression on myeloid cells, and metabolic programs), rather than for providing ready-to-execute clinical prediction rules. For actionability, the field needs standardized TAM subset definitions tied to the technology used (IHC vs scRNA-seq reference vs spatial deconvolution) and explicit experimental validation pipelines.

The review’s emphasis on refined biomarkers and single-cell/spatial analyses supports this direction .

3) Evidence-weighted takeaways (what to keep, what to doubt)

Keep: TAM functional plasticity + spatial organization are central; moving beyond binary M1/M2 is justified by macrophage biology guidance .
Keep: TAM checkpoint phenotypes can directly suppress tumor immunity (e.g., PD-1 on TAMs inhibits phagocytosis and tumor immunity) .
Keep: Biomarkers are promising but must be subset-, platform-, and tumor-context specific; pan-cancer atlas approaches support that TAM programs track with response patterns .
Doubt/inspect: Translational generalization from depletion/reprogramming across cancers and models; combination trials can fail if TAM-targeting disrupts other immune cell differentiation pathways (e.g., DC differentiation interference) .

4) “How to falsify” the review’s central claims (most realistic disproof tests)

A falsification program for TAM-centered “application” should not only show that TAM depletion/reprogramming “moves markers,” but that it changes causally relevant tumor–immune dynamics in human-relevant contexts.

Examples of disproof targets that directly correspond to mechanisms emphasized in the review:

Phagocytosis suppression mechanisms: show that macrophage checkpoint blockade (e.g., PD-1 on TAMs) does not improve TAM phagocytosis or anti-tumor immunity despite on-target phenotypic changes .
Subset-specificity: demonstrate that scRNA/spatial-defined TAM subsets do not predict prognosis/response once measured with matched assay pipelines (platform harmonization) .
Combination safety/immune context: show that CSF1R-pathway inhibition does not impair dendritic differentiation pathways critical for ICI efficacy synergy (or that such impairment does not affect clinical outcomes) .

5) Optional follow-up: browse author-centric BGPT perspectives

Feedback:

Updated: April 20, 2026